Journal
CELLS
Volume 11, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/cells11071105
Keywords
airway epithelium; alarmin cytokines; TSLP; IL-33; IL-25; asthma
Categories
Ask authors/readers for more resources
The airway epithelium is the first line of defense for the lungs, detecting environmental threats and releasing alarmin cytokines that play important roles in inflammation. Blockade of TSLP and IL-33 is beneficial for asthma treatment, but further research is needed to determine which subsets of asthma patients will benefit the most from anti-alarmin therapy.
The airway epithelium is the first line of defense for the lungs, detecting inhaled environmental threats through pattern recognition receptors expressed transmembrane or intracellularly. Activation of pattern recognition receptors triggers the release of alarmin cytokines IL-25, IL-33, and TSLP. These alarmins are important mediators of inflammation, with receptors widely expressed in structural cells as well as innate and adaptive immune cells. Many of the key effector cells in the allergic cascade also produce alarmins, thereby contributing to the airways disease by driving downstream type 2 inflammatory processes. Randomized controlled clinical trials have demonstrated benefit when blockade of TSLP and IL-33 were added to standard of care medications, suggesting these are important new targets for treatment of asthma. With genome-wide association studies demonstrating associations between single-nucleotide polymorphisms of the TSLP and IL-33 gene and risk of asthma, it will be important to understand which subsets of asthma patients will benefit most from anti-alarmin therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available